2013 Conference on Retroviruses and Opportunistic Infections*

March 3-6, 2013; Atlanta, Georgia
Join expert faculty members Joseph J. Eron, Jr., MD; Joel E. Gallant, MD, MPH; William G. Powderly, MD; Kimberly Y. Smith, MD, MPH; Kathleen E. Squires, MD; and Andrew R. Zolopa, MD, for a review of the HIV highlights of this important annual conference.

Clinical Impact of New Data From Atlanta: Comorbidities and Coinfection

Capsules

A robust early immunologic response significantly reduced the risk for virus-related non-AIDS–defining cancers, underscoring the need for effective ART, particularly among patients with poor immunologic status.

Released: March 7, 2013

Increased risk of HSILs detected by random biopsy was associated with greater number of HSILs detected by standard biopsy, whereas oncogenic HPV infection, provider/venue were associated with increased risk of HSILs detected by random or standard biopsy.

Released: March 10, 2013

High incidence of early deaths in patients initiating first-line ART during antifungal induction therapy for CM vs deferring ART until ≥ 5 weeks after CM diagnosis.

Released: March 14, 2013

A 4-month regimen with twice-weekly rifapentine 900 mg plus moxifloxacin in the continuation phase was safe but demonstrated inferior efficacy compared with an isoniazid-containing control regimen.

Released: March 10, 2013

In this small dose-finding study, rifampin doses up to 35 mg/kg were safe, well tolerated, and more active than the currently used 10-mg/kg dose in patients with newly diagnosed TB.

Released: March 10, 2013

Nearly 90% of HCV treatment-naive patients and previous relapsers met the criteria for response-guided therapy and received a shortened treatment duration, of whom 75% attained SVR12.

Released: March 8, 2013

SVR8 attained by 93% to 96% of patients in the 12-week arms; both regimens safe and generally well tolerated, with anemia and grade 3/4 bilirubin increases in the RBV-containing treatment arms only.

Released: March 10, 2013

In a single-center pilot study, a 12-week course of telaprevir and peginterferon/ribavirin in MSM with acute genotype 1 HCV infection was associated with an SVR24 rate of 79%.

Released: March 10, 2013

Rates of virologic suppression in both plasma and cerebrospinal fluid were also lower in patients who received CNS-targeted vs non-CNS–targeted therapy, possibly due to lower CD4+ cell count nadir and higher prevalence of HCV coinfection in patients who received CNS-targeted therapy.

Released: March 6, 2013

In interim analysis, 82% of HCV treatment–naive patients and 91% of previous relapsers coinfected with HIV attained HCV RNA below lower limit of quantitation with faldaprevir plus peginterferon/ribavirin at Week 12 of therapy.

Released: March 10, 2013

Non-AIDS–defining cancer diagnoses occurred approximately 7 months earlier in HIV-infected adults vs HIV-uninfected adults.

Released: March 8, 2013

Modelling data suggest relative risk for CVD or CHD increased slightly faster in HIV-infected patients vs general population controls, but relative risk for MI was not increased.

Released: March 7, 2013

Preferential HCV reinfection of HIV-infected MSM with genotypes other than the primary infection suggests original infection confers partial immunity to similar genotype.

Released: March 10, 2013

The use of interventions post-MI, including CVD risk-lowering medications and invasive cardiovascular procedures, has increased since 1999 for HIV-infected patients.

Released: March 7, 2013

Greater mortality risk reduction was observed with exposure to atorvastatin and rosuvastatin—considered potent statins—as compared with all statins.

Released: March 8, 2013
Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Educational grant provided by:
AbbVie
Gilead Sciences
Merck & Co., Inc.
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?